harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving activity against
Company profile
Ticker
HARP
Exchange
Website
CEO
Gerald McMahon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
473458693
HARP stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Mar 24
EFFECT
Notice of effectiveness
12 Mar 24
EFFECT
Notice of effectiveness
12 Mar 24
EFFECT
Notice of effectiveness
12 Mar 24
25-NSE
Exchange delisting
11 Mar 24
POS AM
Prospectus update (post-effective amendment)
11 Mar 24
POS AM
Prospectus update (post-effective amendment)
11 Mar 24
POS AM
Prospectus update (post-effective amendment)
11 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Mar 24
Latest ownership filings
SC 13G
GLAZER CAPITAL, LLC
18 Mar 24
SC 13D/A
GAMCO INVESTORS, INC. ET AL
13 Mar 24
4
Vijay K Lathi
11 Mar 24
4
LAUREN P SILVERNAIL
11 Mar 24
4
RONALD HUNT
11 Mar 24
4
Luke Nathaniel Walker
11 Mar 24
4
Scott Dunseth Myers
11 Mar 24
4
Mark Chin
11 Mar 24
4
JONATHAN G DRACHMAN
11 Mar 24
4
Andrew R Robbins
11 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.94 mm | 17.94 mm | 17.94 mm | 17.94 mm | 17.94 mm | 17.94 mm |
Cash burn (monthly) | 5.18 mm | 2.76 mm | 4.05 mm | 3.26 mm | 5.51 mm | 5.78 mm |
Cash used (since last report) | 34.45 mm | 18.36 mm | 26.93 mm | 21.70 mm | 36.67 mm | 38.48 mm |
Cash remaining | -16.50 mm | -413.40 k | -8.99 mm | -3.76 mm | -18.73 mm | -20.54 mm |
Runway (months of cash) | -3.2 | -0.1 | -2.2 | -1.2 | -3.4 | -3.6 |
Institutional ownership, Q3 2023
95.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 4 |
Closed positions | 17 |
Increased positions | 1 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 4.55 bn |
Total shares | 16.11 mm |
Total puts | 0.00 |
Total calls | 24.09 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Leaf Ventures III | 3.91 mm | $2.69 mm |
MPM BioVentures 2014 | 3.40 mm | $77.02 mm |
Arix Bioscience | 3.24 mm | $2.23 mm |
Artal International S.C.A. | 2.35 mm | $1.61 mm |
Integrated Core Strategies | 1.97 mm | $1.60 mm |
MPM Oncology Impact Management | 319.67 k | $1.29 bn |
Sio Capital Management | 168.02 k | $677.11 mm |
BEN Franklin Resources | 132.33 k | $533.28 mm |
Vanguard | 113.36 k | $456.85 mm |
Artal | 100.00 k | $403.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Merck & Co | Common Stock, par value $0.0001 | Buy | Acquire P | Yes | No | 23 | 21,397,205 | 492.14 mm | 1,000 |
11 Mar 24 | Silvernail Lauren P | Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,000 | 0.00 | 0 |
11 Mar 24 | Silvernail Lauren P | Director Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.657 | 2,300 | 15.31 k | 0 |
11 Mar 24 | Silvernail Lauren P | Director Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.2 | 2,033 | 32.93 k | 0 |
11 Mar 24 | Luke Nathaniel Walker | Common Stock | Sale back to company | Dispose D | No | No | 0 | 135,000 | 0.00 | 0 |
11 Mar 24 | Luke Nathaniel Walker | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.9 | 10,000 | 89.00 k | 0 |
11 Mar 24 | Luke Nathaniel Walker | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 10.8 | 30,500 | 329.40 k | 0 |
11 Mar 24 | Myers Scott Dunseth | Common Stock | Sale back to company | Dispose D | No | No | 0 | 22,665 | 0.00 | 0 |
11 Mar 24 | Myers Scott Dunseth | Director Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.657 | 4,600 | 30.62 k | 0 |
11 Mar 24 | Myers Scott Dunseth | Director Stock Option Common Stock | Sale back to company | Dispose D | No | No | 20.1 | 2,033 | 40.86 k | 0 |
Press releases
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
11 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGAN
10 Feb 24
INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNW
6 Feb 24
INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, JNPR, TGAN, TAST
6 Feb 24
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BBAI, HARP, FGH, PGTI
5 Feb 24